Part 3/8:
While this may challenge Australia's export sector, it exemplifies a broader U.S. directive to restore manufacturing within its borders. Critics note that such measures could adversely affect Australia's pharmaceutical industry, which heavily relies on exporting to the U.S., especially in generics. Moreover, there’s concern about Australia’s current dependency on China for drug manufacturing, posing strategic risks.